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Abstract
Glioblastomas (GBM) may contain a variable proportion of active cancer stem cells (CSCs) capable of self-renewal, of
aggregating into CD133+ neurospheres, and to develop intracranial tumors that phenocopy the original ones. We
hypothesized that nucleostemin may contribute to cancer stem cell biology as these cells share characteristics with normal
stem cells. Here we report that nucleostemin is expressed in GBM-CSCs isolated from patient samples, and that its
expression, conversely to what it has been described for ordinary stem cells, does not disappear when cells are
differentiated. The significance of nucleostemin expression in CSCs was addressed by targeting the corresponding mRNA
using lentivirally transduced short hairpin RNA (shRNA). In doing so, we found an off-target nucleostemin RNAi (shRNA22)
that abolishes proliferation and induces apoptosis in GBM-CSCs. Furthermore, in the presence of shRNA22, GBM-CSCs failed
to form neurospheres in vitro or grow on soft agar. When these cells are xenotransplanted into the brains of nude rats,
tumor development is significantly delayed. Attempts were made to identify the primary target/s of shRNA22, suggesting a
transcription factor involved in one of the MAP-kinases signaling-pathways or multiple targets. The use of this shRNA may
contribute to develop new therapeutic approaches for this incurable type of brain tumor.
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Introduction
Glioblastoma multiforme is one of the most malignant and
common of all astrocytic tumors [1]. The growth pattern of GBM
is highly infiltrative, rendering a surgical cure very difficult and
resulting in very poor survival outcomes that have improved only
marginally in the past several decades [2]. The cancer stem cell
hypothesis suggests that tumors are organized in a hierarchy with a
subpopulation of CSCs responsible for tumor progression,
maintenance, and recurrence [3]. Cells with stem-like properties
were initially identified in acute myeloid leukaemia [4], and at
present their existence has been confirmed in breast cancer [5],
medulloblastoma and glioblastoma [6], prostate cancer [7],
melanoma [8], ovarian cancer [9], head and neck squamous
carcinomas [10], colon cancer [11], pancreatic cancer [12] and
lung cancer [13], among others. In glioblastoma, relapses normally
follow treatment, probably because CSCs are highly infiltrative,
selectively resistant to radiotherapies, chemotherapies [14,15,16],
immunotherapies [17], and promote angiogenic activity. More-
over, chemo- and radio- therapies may prime brain tumor CSCs
to enhance their stem-cell-like characteristics [18]. This population
of CSCs is highly tumorigenic and phenocopy the original tumor
in rodent xenograft models [19,20]. Approaches to force CSCs to
differentiate to cells with limited, or no cell division attributes, by
exposing them to bone morphogenetic proteins for example, were
used to render them more vulnerable to conventional therapies,
and showed considerable efficacy in mouse models [21].
Understanding the basic biology of cancer stem cells is a key
feature before moving into putative treatments to eliminate them.
Nucleostemin is a GTP-binding protein, so called because of its
nucleolar localization and preferential expression in stem cells
[22]. Although the protein is predominantly present in embryonic
and adult stem cells, it is also expressed in several transformed cell
lines and tumors [23,24]. Nucleostemin, on the other hand, is
abruptly down-regulated during differentiation prior to terminal
cell division. This protein was first identified in adult rat neural
stem cells, and has been implicated in cell-cycle progression [22].
Several nucleostemin-binding proteins have been identified,
including p53, MDM2 and the telomeric repeat binding factor 1
(TRF1) [22,25,26]. Alterations in nucleostemin expression levels
cause a decrease in the proliferation rate of cells, in both p53
dependent and independent manners, [22,26–28]. The protein is
indispensable for early embryogenesis [29] but is also important in
adult neural stem cells [30]. Some studies have shown that
depletion of nucleostemin is associated with a limited tumorigenic
capacity in both HeLa and PC-3 cells [31,24]. Beside its
implication in the regulation of cell proliferation, several additional
roles have been assigned to nucleostemin such as telomere length
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regulation by promoting the degradation of TRF1 [25], processing
of pre-rRNAs [32] and maintenance of nucleolar architecture
[33].
Our intention was to explore the role of nucleostemin in
human GBM-CSCs using lentivirally transduced short hairpin
RNAs (shRNAs) to severely reduce its presence in the cells. The
CSCs depleted of nucleostemin expression (shRNA18) did not
result in the profound reduction of cell proliferation and
increased apoptosis that we had expected. Instead, an off-target
lentivirus (shRNA22) abolished proliferation, self-renewal and
survival of CSCs. Also, the presence of this shRNA significantly
delayed CSCs tumorigenic capacity when xenografted in nude
rat brains.
Results
Expression of nucleostemin in two human-glioblastoma-
derived cancer stem cell lines
Two cultures enriched for cancer stem cells were derived from
human brain tumor specimens (samples CSCs-5 and CSCs-7).
Both cell lines grew exponentially and formed neurospheres even
when seeded at low density, indicating a strong self-renewal
capacity. The neurospheres were positive to CD133 (Fig. 1A;
green), nestin (Fig. 1A; red), Sox2 (Fig. 1B; green) vimentin
(Fig. 1B; red), and nucleostemin (Fig. 1B; pink) neural stem cell
markers. Nucleostemin was present in the nucleus of 88% of
CSCs-5 and CSCs-7 cells, as determined by immunofluorescence
assays (Fig. 1C). A large percentage of cells (76%) were also
positive for CD133, and even higher percentages were obtained
for nestin, vimentin and Sox2 (over 95%), the latter involved in
self-renewal and proliferation of stem cells. CD15 was a marker for
54% of CSCs-5 and 69% for CSCs-7. The multipotency of these
two cultures was demonstrated as the neurospheres grown in
differentiation-inducing medium displayed typical morphological
differentiation towards all the three neural lineages – astrocytic,
neuronal and oligodendrocytic, as assessed by positivity for b-III-
tubulin [34] and MAP2 (neuronal) (Fig. 1D red, and S1 red),
GFAP (astrocytic) (Fig. 1D green), and NG2 (oligodendrocytic
precursor) (Fig. S1 green) antigens respectively. Nevertheless, the
differentiated cells did not loose expression of nucleostemin
(Fig. 1E), despite not expressing any of the other stemness related
genes (data not shown). The karyotypic analyses showed several
alterations reflecting transforming activity, and the clonogenicity
assays in soft agar indicated development of many colonies.
We then explored the potential of both CSCs-5 and CSCs-7 to
form tumors after orthotopic xenogratf in immunodeficent rat
brains. After injecting 56105 cells intra-cranially, both cell lines
formed large tumors in 100% of the cases (n = 12 for CSCs-5 and
11 for CSCs-7), followed by magnetic resonance imaging (MRI)
(Fig. 1F). The tumors were highly infiltrative (Fig. S2). Explants
from these gliomas were serially transplanted into the brains of
other nude rats and generated lethal tumors that were equally
enriched in CSCs, demonstrating a high capacity for self-
renewal. The mean survival times of the hosts were 6064 days
with CSCs-5 and 81611 days for CSCs-7 cells (Fig. 1G).
Histopathological analyses of xenografts showed the general
characteristic features of GBM, as pseudopalisade and focal
necrosis, high cellularity, high expression of EGFR and high
proliferative index (MIB-1). Patients and xenografts samples
show similar expression levels for all the markers, including
medium (patient/xenograft 5) and low (patient/xenograft 7)
expression for p53, and very low, if any, for p16 (Fig. S3). The
results show that the transplanted tumors in the rats were
phenocopies of the original patient tumors.
Characterization of the shRNAs designed to target
human nucleostemin
The nucleostemin gene has 15 exons, and as it undergoes
alternative splicing produces three different mRNA transcripts.
Except for the exon 1, these variants have similar sequences.
Therefore, for designing specific primers to knock-down all three
variants, we have chosen primers in common sites of exons 4, 10,
13 and 15 (Fig. 2A). We targeted nucleostemin by infection with
lentivirus expressing an shRNA against the nucleolar protein. Five
different shRNAs with perfect complementary sequences in the
human nucleostemin mRNA were introduced to CSCs-5 and
CSCs-7 cells. Three of the five shRNAs were chosen for further
characterization: shRNA18, shRNA20 and shRNA22. The RT-
PCR and western blot analysis revealed that while shRNA18
caused a significant reduction in nucleostemin mRNA (78%) and
protein levels (51%), both shRNA20 and shRNA22 did not seem
to affect the levels of the mRNA and protein, when normalized to
the corresponding respective GAPDH (mRNA) and actin (protein)
controls (Fig. 2B). The results suggest off-target binding of both
shRNA20 and shRNA22. Alternatively, relatively minor reduc-
tions of nucleostemin messenger levels via target effect could have
dominant effects on an assay if the output is very dose-sensitive to
levels of this particular protein. We designed an assay, based upon
colony formation in soft agar, to distinguish between the two
possibilities. The expression of shRNA18 in CSCs-5 or CSCs-7
does not inhibit colony formation in soft agar, while expression of
shRNA22, and to a lesser extent shRNA20, drastically reduced the
number of colonies grown in this type of medium (Fig. 2C and
2D). If shRNA22 was causing a minor reduction in the
nucleostemin message, and this triggered a major inhibition of
growth because the pathway involved was very sensitive to minor
level reductions of the messenger or protein, we should expect a
similar effect when cells are either infected with shRNA18 alone,
or when cells are simultaneous infected with both shRNA18 and
shRNA22. That is, a large number of colonies growing.
Conversely, if a true off-target effect were operating here, the
result of this combination would be the opposite, as the real target
would be different from nucleostemin, and we would observe as
few colonies growing in soft agar as the ones observed when
shRNA22 was used alone. The infection of cells with a lentivirus
not carrying an shRNA was used as a control. The measurement
of the number of CSCs-5 colonies formed in soft agar after
different combined treatments gave the following results (Fig. 2E):
a high number of colonies for the control shRNA (shRNACo) and
for the combination shRNACo+shRNA18, as expected, and a low
number of colonies for both shRNACo+shRNA22, and
shRNA18+shRNA22. Performing this experiment, we were able
to discriminate between the possibilities of all shRNAs targeting
nucleostemin to different degrees or, the shRNA22 having a
different target. If the effect was due to the low level of inhibition,
the co-expression of the shRNA18 and shRNA22 should mask the
effect of the latter, since shRNA18 would inhibit stronger the
expression of the nucleostemin gene. On the other hand, if the
effect was off-target, we would appreciate the consequences of
shRNA22 independently of the expression of shRNA18. The
results show clearly that shRNA22 induces his effect independently
of the expression of shRNA18, indicating that is due to an off-
target effect. We therefore ruled out the hypothesis of a very minor
reduction of nucleostemin by shRNA22 having a dominant
negative effect in cell growth. We believe that the growth
inhibition effect of shRNA22 in soft agar is due to a bona fide off
target effect.
Depletion of nucleostemin by shRNA18, did not significantly
reduce the S phase cell population as indicated by the level of
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BrdU uptake after a 15 min-pulse (Fig. 3A) or the total population
of cells cycling captured by a 20 h BrdU treatment (Fig. 3B). The
other two shRNAs: shRNA20 and shRNA22, having a very low, if
any, inhibition of expression, displayed a consistently lower
percentage of S phase and cycling cells. As demonstrated by
growth curve assays, the total number of cells infected with the
control lentivirus lacking shRNA-expressing insert (shRNACo)
increased several fold over six days. The shRNA20 or shRNA22
infected cells did not increase in number, or even decrease
considerably (Fig. 3C and 3D), while CSCs infected with
shRNA18 behaved much closer to control cells than to shRNA20
and shRNA22. The results suggest an implication of the primary
target of shRNA22, and to a slightly lesser extent to the shRNA20
hit, in sustaining growth and survival of human GBM-CSCs. We
are not certain about shRNA20 and shRNA22 sharing a primary
target, despite the physical closeness of the original shRNA20 and
shRNA22 sequences in the nucleostemin gene. Although only 66
nucleotides separate these two sequences, a human sequence
alignment search taking into account the 66 nucleotides between
them did not reveal any match besides nucleostemin.
The off-target shRNA20 and shRNA22, induce apoptosis
preferentially in CD133+ CSCs and impairs neurosphere
formation
The presence of these shRNAs affect not only cell proliferation
but also cellular survival. We quantified the percentage of
apoptotic cells in both CSCs-5 and 7 populations following
shRNACo, shRNA18, shRNA20 and shRNA22 lentiviral infec-
tion. 7-AAD/annexin V-staining revealed a preferential apoptosis
in CD133+ cells in both CSC-5 and 7 populations (Fig. 4A and
4B); the relative values with respect to the controls for CSCs-5 and
CSCs-7 are shown in Table 1. Also the percentage of CD133+ cells
is reduced in both CSCs-5 and CSCs-7 populations following
shRNA20 and shRNA22 lentiviral infection (Fig. S4). These
results suggest that the primary target of shRNA22 and shRNA20
is a survival factor for GBM-CSCs preferentially expressed in
CD133+ cells.
Sharing certain key characteristics of normal stem cells, CSCs
are capable of self-renewal, which allows sustained maintenance of
this subpopulation and expansion of the corresponding tumor.
Neurosphere formation capacity after treatment with the different
shRNAs was measured (Fig. 4C and 4D). Practically no spheres
were formed by cells treated with shRNA22 and very few by
ShRNA20 treated cells in both CSCs-5 and 7 populations.
Neurospheres developed in 100% of the control groups. These
results, together with our observations that CSCs failed to
proliferate and underwent apoptosis, suggest that the primary
target of shRNA22 and shRNA20 is required for self-renewal of
glioblastoma cancer stem cells.
The off-target shRNA22 significantly reduces the
tumorigenic potential of CSCs-5
We examined the effect of infecting CSCs-5 cells with control
lentiviruses or lentiviruses expressing shRNA22. Following puro-
mycin selection, 56105 cells were injected into the brains of nude
rats. All animals bearing control cells, that is cells infected with
empty lentivirus, (n = 3) developed large tumors, followed by
magnetic resonance, and died in 6361 days, not very different
from uninfected CSCs-5 (6164 days, n = 12). In contrast, the
animals injected with cells expressing shRNA22 (n = 6), developed
significantly smaller tumors, being the median volume of
148 mm3, while the mean value of tumors expressing shRNACo
were 358 mm3 (Fig. 5A and 5B). The Kaplan-Meier survival plot
indicates a significant difference between the shRNACo and
shRNA22 treated tumoral cells, with a mean survival of the latter
of 7162 days (Fig. 5C). Thus, the presence and expression of
shRNA22 in CSCs appears to be important for attenuating tumor
progression.
The effect of shRNA22 does not seem to be exclusive for
CSCs
We attempted to determine the effect of shRNA22 in glioma
cells with no CD133+ stem properties such as U87MG and
U373MG human glioma cell lines. We assessed their clonogenic
potential by soft agar assay following shRNACo and shRNA22
lentiviral infection. A significant reduction in the average number
of colonies was observed when shRNA22 was expressed in
U373MG (down to 1%), and to a lesser extent when in the
U87MG glioma cell line (down to 41%) (Fig. 6A). We also
measured cellular survival by estimating the percentage of
apoptotic cells in both U373MG and U87MG cell lines following
shRNACo, and shRNA22 lentiviral infection. 7-AAD/annexin V-
staining revealed preferential apoptosis in U373 cells in a similar
behaviour to CSCs. On the other hand, U87MG cells appeared
rather resistant to apoptosis (Fig. 6B). The results suggest that
although shRNA22 may attenuate tumoral growth in glioma cells
in general, its impact may depend upon the cell type. The finding
that shRNA22 effect is not limited to CSCs is important when
designing strategies to eliminate all cancer cell types that build up a
highly heterogeneous tumor such as glioblastoma.
Attempts to identify the primary target of shRNA22
We carried out a genomic search for sequences, other than
nucleostemin, with different degrees of homology with shRNA22
nucleotides. For this we used the basic local alignment search tool
(BLAST) and we select four candidates: PCLO, involved in
neurotransmisor release; HSPA13, member of the chaperon
family HSP70; SEC22C, involved in vesicular traffic; and CNOT1
related to transcription and mRNA degradation. Of the 21
nucleotides, 14 were a perfect match in all cases except CNOT,
with a 13 nucleotides match. However, not one of the four
candidates was the primary target for shRNA22 as measured by
qRT-PCR (data not shown) as no differences were observed in the
concentration of their mRNA’s in the presence or absence of
shRNA22 related to shRNACo.
To determine genome-wide differentially expressed genes in
CSCs-5 after shRNA22 infection, we used Affymetrix GeneChip
Gene 1.0 ST Array System containing approximately 28.869
human genes, including the 39 untranslated region (UTR) of the
mRNAs that could be a target for binding in a micro (mi)RNA-like
Figure 1. CSCs-5 and CSCs-7 characterization. A. CSCs-5 and CSCs-7 neurospheres expressing CD133 (green) and nestin (red). Scalebar: 50 mm.
B. CSCs-5 and CSCs-7 cells showing the expression and cellular localization of Sox2 (green), vimentin (red) and nucleostemin (purple). Scalebar:
10 mm, and quantitative plot (C) of the stem cell markers CD133, nestin, vimentin, Sox2, nucleostemin and CD15 in CSCs-5 (gray) and CSCs-7 (green).
D. Neuron (b-III-tubulin, pink-red) and astrocytic (GFAP, green) differentiation capacity of CSCs-5 and CSCs-7. Scalebar: 50 mm. E. Nucleolar
nucleostemin expression in stem or differentiatiated CSCs-5 (gray) and CSCs-7 (green) cells. F. Magnetic resonance imaging of in vivo tumors
developed from CSCs-5 and CSCs-7 (yellow arrowheads point to the tumor), and Kaplan-Meier survival analysis (G) of immunodeficent rats, after
CSCs-5 (red) or CSC-7 (green) orthotopic xenografts.
doi:10.1371/journal.pone.0028753.g001
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manner. As a result we identified 182 genes down-regulated in
CSCs-5 treated with shRNA22 in relation to shRNACo (Table
S1). As expected, nucleostemin was not among the down-regulated
genes. Attempts to group the genes with shRNA22 hits by function
(based on Gene Ontology and signaling pathway data) did reveal
the presence of 26 genes involved in regulation of transcription
among the silenced genes, and 56 DNA binding proteins (Fig. 7A).
The signal transduction pathway with more genes down-regulated
was the MAPK kinases pathway (Fig. 7B). Although the results so
far are not conclusive, an indication that shRNA22 may be
involved in silencing a transcription factor implicated in one of the
MAP-kinases signaling-pathways can be suggested. Alternatively,
multiple target effects are also a strong possibility for shRNA22, in
a similar fashion to micro RNAs.
Discussion
The similarities and differences between SCs and CSCs have
been the source of much contention [35,36,37]. Brain CSCs
resemble neural SCs in terms of phenotype, signaling and
behaviour in vitro [38], but it is currently unclear whether the
CSCs are, in fact, bona fide stem cells. Experimental characteriza-
Figure 2. Nucleostemin-directed shRNAs effect in CSCs. A. Schematic representation of the 3 nucleostemin transcript variants and exons.
Arrowheads point to each designed shRNA. B. Nucleostemin mRNA (red) and protein (blue) quantification in CSCs-5 treated with shRNACo, shRNA18,
shRNA20 and shRNA22. C. shRNAs effect on CSCs-5 and CSCs-7 soft agar colony-forming ability, and its quantitative analysis (D). E. Soft agar colony
counts in double-infections to determine the nucleostemin-specificity of shRNA22. ** p#0.05; *** p#0.001.
doi:10.1371/journal.pone.0028753.g002
Figure 3. shRNAs effect in the proliferation kinetic of CSCs. A. Number of phase-S or total-cycling (B) CSCs-5 (grey) and CSCs-7 (green) cells
treated with the different shRNAs. C. Number of viable cells on DIV 0, 3 and 6 in CSCs-5 and CSCs-7 (D) treated with the different shRNAs. ** p#0.05;
*** p#0.001.
doi:10.1371/journal.pone.0028753.g003
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tions of cancer stem cell populations may help in these matters. In
rats, nucleostemin is highly expressed in the nucleoli of central
nervous system SCs, but not in their differentiated progeny, as the
gene seems to be abruptly shut off during differentiation prior to
terminal stages [22]. Our observations of nucleostemin being
expressed even after CSCs were forced to differentiate in culture,
implies a new signature for CSCs and a significant difference with
SCs, not previously reported.
We used an RNAi approach to specifically promote degradation
of nucleostemin mRNA. Previous data has shown that knocking-
down nucleostemin expression caused a severe decline in cell
proliferation in bladder cancer cells [39] and reduced the sphere-
forming ability in human breast cancer stem cells [40]. A
significant reduction in cell-cycle progression in different types of
human brain tumors and in human glioblastoma derived cell lines
was also reported [41]. However, we found that the only shRNAi
that efficiently reduces the protein, does not suppress cell cycle
progression, does not decrease growth of CSCs cultures, and does
not decrease the number of colonies formed in soft agar, as
compared to controls infected with an empty lentivirus. The
discrepancies could be due to differences in the knocking-down
Figure 4. shRNAs effect in the viability of CSCs. A. Apoptosis induced by shRNAs in CSCs-5 and CSCs-7 (B) CD133+ (red) or CD1332 (blue)
populations. C. Neurosphere forming-ability of CSCs-5 and CSCs-7 (D) cells, treated with the different shRNAs. ** p#0.05; *** p#0.001.
doi:10.1371/journal.pone.0028753.g004
Table 1. Preferential apoptosis in CD133+ cells in both CSC-5
and CSC-7 cultures.
CD133+ CD1332
CSCs-5 Mean s.d. Mean s.d.
ShRNACo 1 0,1915 1 0,4633
ShRNA18 1,7582 0,2432 0,7005 0,2498
ShRNA20 4,8462 1,7494 2,6928 0,3333
ShRNA22 4,4463 2,009 1,968 0,2748
CSCs-7
ShRNACo 1 0,3987 1 0,264
ShRNA18 1,5165 0,4393 0,8947 0,2959
ShRNA20 6,9138 2,2152 2,9816 1,4131
ShRNA22 6,6357 0,8982 1,3607 0,2593
doi:10.1371/journal.pone.0028753.t001
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levels of nucleostemin achieved in previous reports (higher than
75% and sometimes more than 90%) and us (51%).
RNAi technology has been widely used in mammalian cells to
suppress the expression level of individual genes, thus helping to
define the functional roles of genes, particularly in diseases. Much
work has centered around shRNA design algorithms, with a focus
on gene-target specificity and efficiency [42,43]. Nevertheless off-
target effects are widespread, and individual shRNAs have been
shown to down-regulate one or several other ‘‘unwanted’’ genes
[44,45], sometimes by binding in a micro (mi)RNA-like manner to
the 39 UTRs of mRNAs [46]. We found than shRNA22 is binding
to other/s than the intended target gene. Off-target effects
reported in previous RNAi studies were mediated by partial
complementarity between shRNAs and the 39 UTRs of off-target
genes, involving a heptamer or hexamer ‘seed’ match of the
shRNA strand at the 59 end at positions 2 to 8 or 2 to 7,
respectively [46,47]. The mechanism is similar to that of miRNAs.
Although the BLAST library used included the 39UTRs of the
messengers, a 7-nucleotide match parameter was not included in
the screen analysis, as it would represent a severe relaxation of the
conditions and a large increase in putative matches. A common
primary target for shRNA20 and shRNA22 is presumed, as the
sequences are only 66 nucleotides apart in nucleostemin exon 10.
It is possible that a nucleostemin sequence including the
shRNA22, the region between the two shRNAs and shRNA20
(maybe partially), would also be present in another genomic
region, coding for a different protein whose mRNA secondary
structure would be more accessible to shRNA22 and shRNA20
than the one at the nucleostemin mRNA. Nevertheless, no new
matches beside nucleostemin were found in a human genome-
Figure 5. shRNAs effect in the in vivo tumor-development of the CSCs-5. A. Quantification of the volumes of tumors induced with CSCs-5
cells treated with shRNACo (black) and shRNA22 (red). B. Magnetic resonance imaging of representative examples of tumors after orthotopic
xenografts in nude rat-brains of CSCs-5 cells carrying shRNACo or shRNA22, and Kaplan-Meier survival plot (C) of the immunodeficent rats inoculated
with CSCs-5 (mock, gray), cells carrying shRNACo (black) and shRNA22 (red). *** p#0.001.
doi:10.1371/journal.pone.0028753.g005
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wide search for complementary regions to the two-shRNA
sequences and the nucleotides between them, performed using
the basic local alignment search tool (BLAST).
The gene expression profiling of CSCs-5 in the presence or
absence of shRNA22 did not unequivocally indicate its primary
target. Rather, multiple target effects are a reasonable possibility
for this shRNA. The largest number of genes silenced was related
to the regulation of transcription when hits were grouped by
function, and over-representation of genes involved in the MAPK
signaling pathway were down-regulated by shRNA22 expression.
Over-expression of one or more genes of the MAPK signaling
pathway is common in glioblastomas, and several small molecules
that inhibit the PI3 kinase-Akt signaling pathway are in clinical
development. Although many of these molecules have been
effective in preclinical models, it remains unclear whether this
strategy alone will be sufficient to interrupt the molecular events
initiated and maintained by signaling along the pathways because
of the activation of other pathways that compensate for the
inhibition of the targeted kinase. Attempts have recently been
made to identify genes or pathways whose inactivation, in
combination with the PI3K inhibitors PX-866 and NVPBEZ-
235, might result in a lethal phenotype in glioblastoma multiforme
cells [48]. The identified shRNA22, when expressed in CSCs from
glioblastoma patients, inhibits cell proliferation and self-renewal,
induces apoptosis and significantly reduces their tumorigenic
potential when xenotransplanted into the brains of nude rats. The
fact that the primary target of shRNA22 is not limited to CSCs is
important, because when trying to eliminate a tumor one must
also target the tumor stroma cells and microglia because these cells
contribute to tumor maintenance and progression. The use of this
shRNA alone or in combination with other drugs may represent a
potential clinical therapeutic strategy.
Materials and Methods
Statement for animal care
This study was carried out in strict accordance with the
legislation and guidelines for animal care and handling in Spain
(Spanish Royal Decree 1201/2005 BOE published October 21st
2005), and those from the European Union (2003/65/CE from
the European Parliament and Council July 2003). The protocol
was approved by the Committee on the Ethics of Animal
Experiments of the Autonomous University of Madrid (permit
associated to project SAF 2009-07259 issued in Madrid 11th
March 2009) and by the CBMSO institutional Biosafety
Committee. All surgery was performed under isofluorane gas
anesthesia, and all efforts were made to minimize suffering.
Statement for patient Consent
We obtained two new cancer stem cells lines (CSCs-5 and
CSCs-7) from primary glioblastoma surgical specimens from
patients undergoing resection for newly diagnosed glioma in
accordance with protocols approved by the Institutional Ethic
Committee of the Ramo´n y Cajal Hospital. Written informed
consent to utilize excess tissue for research was obtained from each
patient, and de-identified tissues, to protect anonymity, were used
(permit associated to project SAF 2009-07259, issued in Madrid
the 26th February 2009, Spain).
Statement for microarray data
All data presented here is MIAME compliant and the raw data
has been deposited in the GEO compliant database (Access
number: GSE30448).
Cell isolation and culture
The new cultures, CSCs-5 and CSCs-7, were established from
fresh surgical specimens collected directly from the operating
theatre in PBS plus 0,6% glucose and immediately transported on
ice to the cell culture room and processed as follows: the tumour
pieces were washed and minced finely with small scissors, they
were then incubated in 0,1% trypsin and 0,04% DNase (type II,
Sigma) in PBS for 1 h at 37uC. Digested tissue was washed two
times and mechanically dissociated by passing through fire-
polished Pasteur pippetes. Finally, the cell suspension obtained
was filtered in a 40 mm cell strainer (BD). The number and
viability of the cells were measured with trypan blue assay.
Neurosphere culture was initiated by seeding cells at a density of
16105 viable cells/ml in a proliferation medium consisting of
DMEM:F12 (1:1) supplemented with glutamax (Gibco), 0,5%
albumax I (Gibco), 5 mM hepes (Gibco), 0,6% glucose (Sigma),
N2 (16, Invitrogen), 2 mg/ml heparin (Sigma), 20 ng/ml of both
Figure 6. shRNAs effect in U373MG and U87MG cell lines. A. shRNAs effect on U373MG (black) and U87MG (gray) soft agar colony-forming
ability. B. shRNAs-induced apoptosis in U373MG (black) and U87MG (gray). ** p#0.05; *** p#0.001.
doi:10.1371/journal.pone.0028753.g006
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Figure 7. Gene expression profiling in the presence and absence of shRNA22. A. Significative down- (green), up- (red) and all-regulated
(blue) genes grouped by function of biological processes, or by belonging to signaling pathways (B) induced by shRNA22 in CSCs-5 cells.
doi:10.1371/journal.pone.0028753.g007
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EGF and FGF-2 (Peprotech), aminoacids (L-Ala 44 mM, L-Asn
45 mM, L-Asp 40 mM, L-Glu 40 mM, L-Pro 30 mM) and
gentamicine (0,055 mg/ml). The cultures were grown at 37uC in
a 97% humidity atmosphere containing 5% CO2, and fed twice a
week with a 20% volume of fresh medium. In these conditions,
neurospheres developed in one to two weeks. When the size
reached 200–300 mm, the neurospheres were dissociated with
trypsin-EDTA and re-seeded. U87MG [46] and U373MG [46]
cell lines were grown in DMEM (Gibco) supplemented with 10%
foetal bovine serum (Sigma).
Lentiviral vector production and infection
The shRNA lentiviral vectors against nucleostemin were
commercially obtained from Sigma-Aldrich; (MISSION shRNA
TRCN0000074218, TRCN0000074219, TRCN0000074220,
TRCN0000074221 and TRCN0000074222). We used pLKO.1
as negative control, with no shRNA insert (SHC001, Sigma-
Aldrich). The vectors were co-transfected with pCMV-dR8.74
packaging plasmid and pMD2G envelope plasmid into 293T [46]
cells with optimem, lipofectamine and plus reagent (Invitrogen), to
produce virus. After 24 h, the optimem was changed to CSC
medium, the cells were incubated for 24 h and then the
supernatants were collected, filtered and stored at 280uC. For
infections, 66104 viable cells/cm2 were seeded into optimem
medium and incubated for 6 h. Then, the viral particles (1 ml of
collected supernatant per P100 plate) and 4 mg/ml polybrene were
added and incubated over night. The optimem was changed to
proliferation medium and the cells were incubated for 8 h prior
puromycin treatment (0,8 mg/ml). The cells were incubated for an
additional 96 h to insure that only the infected cells were alive.
Immunocitochemistry
The cells were attached onto poli-lysine (0,0033%, Sigma) and
laminine (10 mg/ml, sigma) coated glass coverslips and fixed with
4% parafolmaldehyde. They were then permeabilizated for
10 min with 0,1% Triton X-100 in PBS and blocked for 20 min
with 0,1% Triton X-100 and 1% FBS in PBS. The followings
antibodies were incubated over night at 4uC: rabbit anti-CD133
(1:100, Abcam), rabbit anti-hNS (1:500, Chemicon), mouse anti-
vimentin (1:200, Roche), rabbit anti-Sox2 (1:200, Chemicon) and
rabbit anti-NG2 (1:200, Chemicon). The following antibodies
were incubated for 1 h at room temeperature: mouse anti-nestin
(1:500, Chemicon), mouse anti-b-III-tubulin (1:2000, Promega),
mouse anti-MAP2 (1:1000, Sigma), and rabbit anti-GFAP (1:1000,
Promega). The coverslips were washed three times and incubated
for 1 h at room temperature with the appropriate secondary
antibody: donkey anti-rabbit IgGs Alexa 488 (1:500, Invitrogen) or
donkey anti-mouse IgGs Alexa 555 (1:500, Invitrogen). For BrdU
labeling, a 20 h pulse of 10 mM BrdU (to mark all cycling cells) or
15 min of 40 mM BrdU (to mark S-phase cells) was used. The cells
were fixed, made permeable with 0,2% Triton X-100 in PBS for
20 min, treated with HCl 1 M for 10 min and HCl 2 M for
20 min, neutralized with Na2B4O7 0,1 M pH 8,5 for 2 min and
blocked with 0,2% Triton X-100 and 1% FBS in PBS for 20 min.
Mouse anti-BrdU antibody (1:100, BD) were incubated for 1 h at
room temperature. In all cases, the nuclei were counterstained
with DAPI. For fluorescence imaging, we used Axiovert200
microscope (Zeiss).
Immunohistochemistry
The tissues were fixed with PFA 4%, paraffin-embedded, and
chopped in to 5 mm slides. The samples were de-paraffinized
and hydrated by sequential washes of 5 min (twice each) in
xylene, absolute ethanol, 95% ethanol, 70% ethanol and water.
Then, antigens were retrieved incubating the samples in citrate
10 mM pH 6 during 10 min at 95uC, cooling down to RT and
washing twice with water and PBS. They were then blocked for
1 hour with 0,3% Triton X-100 and 5% FBS in PBS. The
mouse anti-human nestin (1:500, Chemicon) antibody was
incubated for 1 h at room temperature. The samples were
washed three times and incubated for 1 h at room temperature
with the donkey anti-mouse IgGs Alexa 488 (1:500, Invitrogen)
secondary antibody. The nuclei were counterstained with
DAPI.
Soft agar assay
To evaluate the tumorigenic potential of the cells after the
inhibition of nucleostemin, 26104 viable cells per well were plated
in soft agar in 6-wells plates. Briefly, the base layer was made by
mixing equal volumes of sterile 1% agar, cooled to 40uC, and 26
proliferation medium, to obtain a final solution of 0,5% agar in 16
CSC medium. For the top layer, the agar was diluted to 0,7% in
distilled water, cooled to 40uC and then mixed in equal
proportions with 26 CSC medium. The cells were immediately
added to the mix to yield a final solution of 0,35% agar in 16CSC
medium containing 10.000 cells/ml. No selection agent was added
for this assay. The cells grew for 14 days at 37uC in a humidified
atmosphere containing 5% CO2 and then viable colonies were
stained with 1 ml/well of 600 mg/ml MTT (Thiazolyl Blue
Tetrazolium Bromide, Sigma), photographed, and counted using
ImageJ software (http://rsbweb.nih.gov/ij/).
Secondary neurosphere formation assay
Infected cells were plated at low density (16104 viable cells/ml)
in 96-well plates in proliferation medium with 0,8 mg/ml
puromycin and grew for 9 generations. Then, the wells were
photographed in a bright field with an Axiovert200 microscope
(Zeiss) and visually scored for the number and size of the spheres
generated in each case. ImageJ software was used to set the scale of
the image.
Flow cytometry
A single cell suspension was resuspended in PBS and labeled
with 5 ml per million cells using CD133/2(292C3)-APC antibody
(Miltenyi Biotec) or 10 ml per million cells for the isotype control
antibody (mouse IgG2b-APC, Immunostep research), according to
the manufacturer’s instructions, and analyzed using a FACSCa-
libur (Beckton Dickinson). If necessary, a sequential stain was
made to assay the apoptosis. CD133 marked cells were washed
with 0,5 ml of binding buffer (10 mM Hepes pH 7,4; 140 mM
NaCl, 2,5 mM CaCl) and resuspended in 200 ml of binding buffer
plus 6 ml Annexin V-FITC (BD Pharmingen) and 5 ml 7-amino-
actinomycin D (7-AAD, BD Pharmingen), incubated for 15 min at
room temperature and immediately analyzed. The data collected
was analyzed with FlowJo software.
Real-time quantitative PCR
Cell pellets were collected by centrifugation at 7500 rpm for
5 min at 4uC. The RNA was extracted using TRIzol reagent
(Invitrogen) and analyzed by electrophoresis. The concentration
was estimated using a Nanodrop ND-100 (Thermo Scientific).
cDNA from total RNA (1 mg per sample) was synthesized using the
High capacity cDNA achieve (Applied Biosystems). Equal amounts of
cDNA from each sample were amplified with nucleostemin
TaqMan probe (Hs01015887_g1, Applied Biosystems). A Taq-
Man probe of human house keeping GAPDH (Hs 99999905_m1,
Applied Biosystems) was used for internal control.
A New RNAi against Glioblastoma
PLoS ONE | www.plosone.org 11 December 2011 | Volume 6 | Issue 12 | e28753
Western blot
The cells were lisated in lysis buffer (50 mM Tris-HCl pH 7,5;
300 mM NaCl, 0,5% SDS, 1% Triton X-100 and 10 mM PMSF).
Protein concentration was measured by Dc protein assay (BioRad).
Proteins (25 mg) were separated in 12% SDS-polyacrylamide gel
and transferred to nitrocellulose membranes (Whattman). The
membranes were blocked with 5% fat-free milk powder and 0,3%
tween-20 (Merck) for 1 h at room temperature. The rabbit anti-
hNS (1:5000, Chemicon) and rabbit anti-actin (1:1000, Sigma)
were incubated for 1 h at room temperature. Membranes were
washed four times in 0,3% tween-20 in PBS and incubated for 1 h
at room temperature with the secondary antibody (rabbit Ig-HPR,
1:3000, DAKO). Immunoblots were developed and densitometric
analyses were performed using Quantity One software (Bio-Rad).
Intracraneal xenograft
56105 viable cells, infected and selected, were stereotactically
implanted in 5 ml of PBS to generate orthotopic xenografts as
follows: Nude rats (rnu/rnu, Charles River) were immobilized on a
stereotaxic frame (Kopf) and anaesthetized with a constant flow of
isoflurane, O2 (2 l/min) and N2O (1 l/min). A longitudinal
incision was made and small craneotomy was performed at
4 mm to the right of bregma. The cells were injected at 4 mm depth
from the dural membrane with a Hamilton syringe and an
automatic injector (Stoelting Mod.310) at a rate of 1 ml/min. The
surgical field was cleaned and closed with a surgical stapler.
Microarray analysis
CSCs-5 cells were infected with shRNACo and shRNA22 as
previously described, and exposed to puromycin for 62 h. Then,
the RNA was extracted by RNeasy kit (Quiagen) and its quality
was measured using a 2100B Bioanalyzer (Agilent Technologies).
The cDNA was synthesized using the High capacity cDNA achieve
(Applied Biosystems). We chosen the GeneChip Gene 1.0 ST
Array System for human (Affymetrix), performed in the Genomic
unit of the Parque Cientı´fico de Madrid, following the manufac-
turer’s protocol. Gene ontology analysis was performed by the
same unit using GeneCoDis (http://genecodis.dacya.ucm.es/).
Statistical analysis
The statistical analysis was performed using a two-tailed
Student’s t test (unpaired). Survival analysis of in vivo experiments
was performed by Kaplan-Meier curves.
Supporting Information
Figure S1 MAP2, GFAP and NG2 expression. Differenti-
ated CSCs-5 and CSCs-7 cells showing the neuronal MAP2 (red,
upper panels), astrocytic GFAP (green, upper panels), and
oligodendrocytic precursor NG2 (green, lower panels) markers.
Scalebar: 50 mm.
(TIF)
Figure S2 Invasiveness of tumors. A. Magnetic resonance
imaging showing the infiltrative capacity of the CSCs-5-induced
tumors. Asterisks: inoculation points; arrowheads: tumoral tissue
limit. B. Contralateral hemisphere invasion of CSCs-5 cells. C. As
a contrast, a much better delimited and less invasive tumor
induced by U87MG cells. D. GBM invasiveness confirmation by
histology in both patient-xenograft pairs. Hematoxylin and eosin
staining. 106 objective. E. Pathologic study showing the
pseudopalisading formation and necrosis detail (whiter areas) in
patient and xenograft-7. 106 objective. F. Specific anti-human
nestin staining (green) in xenograft 5 showing GBM cells
infiltrating the cerebral parenchyma. Scale bar indicates 500 mm
in the left and center panels, and 250 mm in the right panel.
(TIF)
Figure S3 Histopathological analysis of both patients
and xenografts tumors. Comparison between xenografts of
both patient-derived CSCs and the original tumors of haematox-
ilin-eosin staining, p53, p16 and EGFR expression, and the
proliferative index (MIB-1).
(TIF)
Figure S4 Death of CD133+ cells. A. Percentage of CD133+
cells in CSCs-5 and CSCs-7 (B) cells treated with the different
shRNAs.
(TIF)
Table S1 Names of the down-regulated genes when cells are
expressing shRNA22, ratio shRNA22/shRNACo, p-value t. test,
gene symbol and mRNA accession-number.
(DOCX)
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